Evidence map›Paper›PMID 32698854›Full record

ArticleBMC endocrine disorders2020

Leu72Met polymorphism of GHRL gene decreases susceptibility to type 2 diabetes mellitus in a Mexican population.

Edgar Alfonso Rivera-León, Mara Anaís Llamas-Covarrubias, Sergio Sánchez-Enríquez, Erika Martínez-López, Mercedes González-Hita, Iris Monserrat Llamas-Covarrubias

Open access · goldAbstract read
In one paragraph

Article in BMC endocrine disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Role of Leu72Met ofNutrients · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Edgar Alfonso Rivera-LeónDepartamento de Biología Molecular y Genómica, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, CUCS, Postal adress: Sierra Mojada 950, Colonia Independencia, CP, 44340, Guadalajara, Jalisco, Mexico.
Mara Anaís Llamas-CovarrubiasDepartamento de Biología Molecular y Genómica, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, CUCS, Postal adress: Sierra Mojada 950, Colonia Independencia, CP, 44340, Guadalajara, Jalisco, Mexico.
Sergio Sánchez-EnríquezDepartamento de Clínicas, Universidad de Guadalajara, Centro Universitario de los Altos, Tepatitlán de Morelos, Jalisco, Mexico.
Erika Martínez-LópezDepartamento de Biología Molecular y Genómica, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, CUCS, Postal adress: Sierra Mojada 950, Colonia Independencia, CP, 44340, Guadalajara, Jalisco, Mexico.
Mercedes González-HitaDepartamento de Biología Molecular y Genómica, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, CUCS, Postal adress: Sierra Mojada 950, Colonia Independencia, CP, 44340, Guadalajara, Jalisco, Mexico.
Iris Monserrat Llamas-CovarrubiasDepartamento de Biología Molecular y Genómica, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, CUCS, Postal adress: Sierra Mojada 950, Colonia Independencia, CP, 44340, Guadalajara, Jalisco, Mexico. irism.llamas@gmail.com.ORCID http://orcid.org/0000-0001-5922-7216
Universidad de Guadalajara · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (T2D) is the most frequent type of diabetes. It has a multifactorial etiology, affecting millions of people worldwide. Ghrelin gene (GHRL) encodes the ghrelin peptide, which promotes food intake, induces body weight and adipogenesis. Several single nucleotide polymorphisms (SNPs) in GHRL gene have been associated with metabolic diseases. A protective effect of the Leu72Met (rs696217) polymorphism has been described for T2D in some populations, but this effect seems to depend on the ethnicity of the patients studied.

methodsThe aim of this study was to investigate the association between the GHRL Leu72Met (rs696217) SNP with the development of T2D and serum ghrelin levels in a Western Mexican population. We performed a case-control study in which we included 284 subjects (159 with previous T2D diagnosis and 125 control subjects (CS)). Leu72Met SNP was genotyped by using PCR-RFLPs technique. Serum ghrelin levels were measured using a commercial enzyme immunoassay. Genotypic and allelic distributions were compared using Chi square test. Student T-test and Mann-Whitney U test were used to compare quantitative variables. Odds ratio (OR) was used to evaluate the association between alleles or genotypes and T2D. Multiple and logistic regression models were performed for adjustment. A two-tailed p-value ≤0.05 was considered statistically significant.

resultsLeu72Leu genotype was more frequent among T2D compared to CS (p < 0.05). After adjusting for age and body composition, there was a significant protective effect of the 72Met allele for T2D development (OR 0.40 IC 95% 0.23-0.70; p ≤ 0.001). Fasting serum ghrelin levels were lower in T2D than CS (p ≤ 0.0001) irrespective of age, body weight and BMI. No associations were found between genotypes and ghrelin serum levels in our population.

conclusionsThe GHRL 72Met allele decreases susceptibility for T2D development in a Western Mexican population. Serum ghrelin levels are lower in T2D independently of Leu72Met polymorphism genotype.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAdultBiomarkersCase-Control StudiesDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGenotypeGhrelinHumansMaleMexicoMiddle AgedPrognosisBiomarkersGhrelinGHRL protein, humanGhrelinLeu72MetPolymorphismType 2 diabetes mellitus

Identifiers

PMID32698854
PMCPMC7374978
OpenAlexW3043896994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.